Lee’s Pharmaceutical Holdings Limited (HK:0950) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lee’s Pharmaceutical Holdings Limited has announced that China’s National Medical Products Administration has accepted their IND application for Recombinant Anfibatide Injection, marking a significant step towards clinical trials for this novel anti-thrombosis drug. The injection, developed by Lee’s Pharm’s subsidiary, Zhaoke Pharmaceutical, demonstrates potential in preventing thrombotic conditions like myocardial infarction. This development underscores Lee’s Pharm’s commitment to innovation in biopharmaceuticals, with a focus on cardiovascular and rare disease therapeutics.
For further insights into HK:0950 stock, check out TipRanks’ Stock Analysis page.